DoD Breast Cancer, Breakthrough Award Level 4 | W81XWH 21 BCRP BTA4

FAQs: DoD BCRP Breakthrough Award Level 4 (W81XWH-21-BCRP-BTA4)

What is the Breakthrough Award Level 4 funding opportunity?

The DoD Breast Cancer Research Program (BCRP) Breakthrough Award Level 4 (funding opportunity number W81XWH-21-BCRP-BTA4) is a highly competitive Department of Defense grant/cooperative agreement intended to support ambitious breast cancer research with a clear line of sight to major, field-changing impact. It is positioned to fund projects with credible breakthrough potential rather than incremental advances.

Who is the sponsoring agency?

The opportunity is offered by the Department of Defense, Department of the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA).

What is the CFDA number for this opportunity?

The listing is under CFDA 12.420 (Science and Technology and other Research and Development).

What is the central goal of Level 4 within the Breakthrough Award structure?

The central goal is to back large-scale projects intended to transform or revolutionize clinical management and/or prevention of breast cancer, with an emphasis on work that could accelerate progress toward ending breast cancer. Projects are expected to credibly promise a fundamentally better direction or intervention than what is already approved or currently in clinical development.

Does Level 4 require a human clinical trial?

Yes. Level 4 is described as the most clinically advanced and operationally demanding tier and it explicitly requires human clinical trials. Proposals are expected to move beyond preclinical research into rigorous testing in people.

Are preclinical-only projects appropriate for this mechanism?

No. The announcement describes Level 4 as requiring human clinical trials and as intended for projects that are operationally and regulatorily positioned to move into or proceed through clinical testing.

What does the program mean by “breakthrough potential”?

In this context, “breakthrough potential” means the research should not be a modest incremental step. The project should credibly promise a new direction or intervention that is fundamentally better than what is already approved or currently in clinical development, with a clear path to major impact.

Do applicants need to define who will benefit from the research?

Yes. Applicants are expected to define the end beneficiaries by specifying the breast cancer patient populations or at-risk individuals who would ultimately benefit if the project succeeds.

What expectations are stated for principal investigator (PI) experience?

Because Level 4 is large-scale and operationally demanding, PIs are expected to demonstrate experience leading large, complex research efforts and show they can successfully implement a clinical project. This can be shown through the PI’s own track record or via an established commitment from a collaborating clinical investigator.

What types of “readiness” evidence are applicants expected to provide?

Applications are expected to show practical readiness, including documentation (when relevant) that the team has access to necessary datasets, human samples, cohorts, and critical reagents needed to deliver the trial and associated analyses.

What does the opportunity emphasize about operational and regulatory preparedness?

Level 4 places a strong emphasis on operational and regulatory preparedness, particularly for projects that require U.S. Food and Drug Administration (FDA) involvement. The mechanism is intended for projects that are not just conceptually ready, but also logistically and regulatorily positioned for clinical testing.

If a project involves an FDA-regulated therapeutic or device, what does the application need to address?

The application is expected to include proof that compliant clinical reagents are available and accessible, that appropriate subject populations can be reached, and that patient recruitment projections are realistic and validated.

Is an IND or IDE submission expected before applying?

Where applicable, the program expects that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) submission to the FDA has been made by the time the application is submitted.

What are recruitment milestones and why do they matter in Level 4?

Recruitment milestones are a major accountability feature of Level 4. Applicants must lay out quarterly enrollment targets across all participating sites in the Statement of Work (Attachment 4). After award, recruitment milestones are formalized with USAMRAA, and continued funding is tied to satisfactory progress against those agreed targets.

Where must quarterly enrollment targets be documented?

Quarterly enrollment targets across all participating sites must be included in the Statement of Work (Attachment 4).

How does USAMRAA engage with awardees after funding regarding enrollment?

After award, teams work with USAMRAA to formalize recruitment milestones. Continued funding is tied to satisfactory progress against the agreed enrollment targets.

Is collaboration between two PIs allowed?

Yes. The opportunity includes an optional Partnering PI model designed for two principal investigators working as true intellectual partners.

What is the difference between the Initiating PI and the Partnering PI?

One PI serves as the Initiating PI and handles most submission-related administrative responsibilities. The Partnering PI is expected to contribute substantially and comparably to the project concept, narrative, and statement of work.

Does the program expect balanced effort and funding between Partnering PIs?

Yes. The program expects balanced effort and typically balanced funding between the two PIs unless there is a clear justification otherwise.

What kind of Partnering PI arrangement does the program say does not fit the intent?

The announcement indicates that arrangements where one PI mainly supplies materials (such as samples, animal models, or investigational agents) while the other PI does most of the research do not fit the intent of the Partnering PI model.

Can one investigator be listed as a Partnering PI on multiple Level 4 applications?

The announcement discourages a single investigator from being listed as Partnering PI on multiple Level 4 applications unless each application tackles clearly distinct research questions.

If funded under the Partnering PI model, how are awards structured?

If funded, each PI is named on an individual award within the recipient organization, reflecting shared leadership and accountability.

What does the program require in terms of team composition?

Applications are expected to include a robust, appropriately staffed research team with the breadth of breast cancer-related expertise needed to conduct a large clinical trial and associated translational, data, and operational work.

Are consumer advocates required to be part of the project team?

Yes. Each application must include two or more breast cancer consumer advocates who are integrated into the project throughout planning and execution, not limited to occasional meeting attendance.

Who can serve as a breast cancer consumer advocate for this award?

Consumer advocates must be individuals diagnosed with breast cancer who are active in advocacy organizations. They must not be employees of participating organizations and are expected to provide independent, objective input focused on patient relevance and real-world impact.

What roles are consumer advocates expected to play?

The announcement describes advocate involvement as focused on relevance, feasibility, recruitment, oversight, and real-world impact for people with or at risk for breast cancer, with integration throughout planning and execution.

Does the opportunity describe any expectations about advocate preparedness?

Yes. The announcement signals that advocates should be sufficiently informed about current breast cancer issues and have the background or training needed to contribute meaningfully to research discussions.

What does “unrestricted eligibility” mean in this listing?

Eligibility is described as unrestricted, meaning it is broadly open to entity types unless otherwise limited by additional eligibility language in the full announcement.

How many awards are expected for this cycle?

The posting indicates an expected single award for this cycle, reflecting the scale and competitiveness typical of Level 4 clinical trial mechanisms.

Is there a stated maximum budget amount for this opportunity?

The award ceiling is shown as 0 in the listing. This typically indicates applicants must rely on the program announcement itself for budget limits and that selecting Level 4 should be driven by scope alignment rather than trying to match a particular dollar figure.

What does the “award ceiling shown as 0” imply for applicants?

Based on the listing description, it implies the specific budget cap is not provided in the listing and applicants should consult the program announcement for budget limits and ensure the project scope aligns with Level 4 expectations.